How WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story

Simply Wall St.12-15

Merck recently reported that the European Medicines Agency’s CHMP has recommended expanding WINREVAIR’s pulmonary arterial hypertension indication in Europe to include higher-risk WHO Functional Class...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591922662?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/288502-main-header/1756255043815","is_english":true,"pubTime":"2025-12-15 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591922662","market":"sg","top_or_hot":-1,"title":"How WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>Merck recently reported that the European Medicines Agency’s CHMP has recommended expanding WINREVAIR’s pulmonary arterial hypertension indication in Europe to include higher-risk WHO Functional Class...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-15 04:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck recently reported that the European Medicines Agency’s CHMP has recommended expanding WINREVAIR’s pulmonary arterial hypertension indication in Europe to include higher-risk WHO Functional Class...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999013999.USD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck","article_id":"2591922662","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/288502-main-header/1756255043815"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591922662","pubTimestamp":1765743562,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Merck recently reported that the European Medicines Agency’s CHMP has recommended expanding WINREVAIR’s pulmonary arterial hypertension indication in Europe to include higher-risk WHO Functional Class II–IV adults, following strong Phase 3 ZENITH data on morbidity and mortality outcomes.\nThis regulatory momentum strengthens WINREVAIR’s position as a differentiated activin signaling inhibitor in a serious disease area, potentially broadening its role as one of Merck’s key growth drivers...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","MRK":"默沙东","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","CHMP":"冠军工业","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4559":"巴菲特持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4550":"红杉资本持仓","BK4588":"碎股","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","BK4087":"商业印刷","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC"},"translate_title":"WINREVAIR在默克(MRK)扩大CHMP支持的PAH适应症如何改变其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHMP":1.5,"MRK":1.5},"content_text":"Merck recently reported that the European Medicines Agency’s CHMP has recommended expanding WINREVAIR’s pulmonary arterial hypertension indication in Europe to include higher-risk WHO Functional Class II–IV adults, following strong Phase 3 ZENITH data on morbidity and mortality outcomes. This regulatory momentum strengthens WINREVAIR’s position as a differentiated activin signaling inhibitor in a serious disease area, potentially broadening its role as one of Merck’s key growth drivers beyond oncology. We’ll now examine how WINREVAIR’s expanded CHMP-backed indication may influence Merck’s pipeline-led growth narrative and post-KEYTRUDA diversification story. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.Merck Investment Narrative RecapTo own Merck, you need to believe its late stage pipeline can offset eventual KEYTRUDA loss of exclusivity while supporting a steady dividend profile. The CHMP backing for WINREVAIR’s broader PAH use reinforces the pipeline led growth story, but it does not change the central near term catalyst of execution on multiple new launches or the key risk that competitors outpace Merck in critical categories. Among recent updates, the Saskatchewan funding decision for CAPVAXIVE ties directly into this theme, highlighting how newer vaccines and specialty drugs like WINREVAIR can build more diversified revenue beyond oncology. Together, these launches sit alongside ongoing M&A and R&D as practical tests of whether Merck’s promised “20 plus growth drivers” can meaningfully soften the future KEYTRUDA cliff. Yet, despite Merck’s progress with WINREVAIR and CAPVAXIVE, investors still need to be aware of the risk that... Read the full narrative on Merck (it's free!)Merck's narrative projects $72.0 billion revenue and $24.3 billion earnings by 2028. This requires 4.2% yearly revenue growth and an earnings increase of about $7.9 billion from $16.4 billion today.Uncover how Merck's forecasts yield a $106.62 fair value, a 6% upside to its current price.Exploring Other PerspectivesMRK 1-Year Stock Price Chart Twenty six members of the Simply Wall St Community value Merck between US$82 and about US$215, underscoring how far opinions can stretch on future outcomes. Many of these views hinge on whether WINREVAIR and other new therapies truly offset KEYTRUDA’s eventual loss of exclusivity, so it is worth comparing several of these perspectives side by side.Explore 26 other fair value estimates on Merck - why the stock might be worth 18% less than the current price!Build Your Own Merck NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Merck research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.Seeking Other Investments?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Find companies with promising cash flow potential yet trading below their fair value.Uncover the next big thing with financially sound penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591922662","isCrawlerRequest":true}